Compositions comprising a bacterial strain of the genus Megasphera and uses thereof

Patent metadata

Field	Value
Publication number	US-11007233-B2
Application number	US-201916714092-A
Country	US
Kind code	B2
Filing date	Dec 13, 2019
Priority date	Jun 14, 2017
Publication date	May 18, 2021
Grant date	May 18, 2021

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing neurodegenerative disorders.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising a dried bacteria strain of the species Megasphaera massiliensis,
wherein the bacteria strain comprises a 16S rRNA gene sequence that has at least 96% sequence identity to the polynucleotide sequence of SEQ ID NO: 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62,
and
a pharmaceutically acceptable excipient, diluent, or carrier.

2. The pharmaceutical composition of claim 1 , wherein the bacteria strain is present in the pharmaceutical composition in an amount that comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU)/g of the bacteria strain with respect to the total weight of the pharmaceutical composition.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral, rectal, nasal, buccal, sublingual, or subcutaneous administration.

4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for delivery to an intestine of the subject.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is encapsulated.

6. The pharmaceutical composition of claim 1 , wherein pharmaceutical composition comprises an enteric coating.

7. The pharmaceutical composition of claim 1 , further comprising an additional therapeutic agent.

8. The pharmaceutical composition of claim 1 , wherein the bacteria strain comprises a 16S rRNA gene sequence that has at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO:2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.

9. The pharmaceutical composition of claim 1 , wherein the bacteria strain comprises a 16S rRNA gene sequence that is the polynucleotide sequence of SEQ ID NO:2.

10. The pharmaceutical composition of claim 1 , wherein the bacteria strain is the bacteria strain deposited under accession number NCIMB 42787.

11. A method of treating a neurological condition associated with neuroinflammation, oxidative stress, or neurodegeneration in a subject in need thereof comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a bacteria strain of the species Megasphaera massiliensis , wherein the bacteria strain comprises a 16S rRNA gene sequence that has at least 96% sequence identity to the polynucleotide sequence of SEQ ID NO:2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62, thereby treating the neurological condition associated with neuroinflammation, oxidative stress, or neurodegeneration in the subject.

12. The method of claim 11 , wherein the bacteria strain is the bacteria strain deposited under accession number NCIMB 42787.

13. The method of claim 11 , wherein administering comprises oral, rectal, nasal, buccal, sublingual, or subcutaneous administration.

14. The method of claim 11 , wherein the bacteria strain comprises a 16S rRNA gene sequence that has at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO:2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.

15. The method of claim 11 , wherein the pharmaceutical composition is encapsulated.

16. The method of claim 11 , wherein the bacteria strain is dried.

17. The method of claim 11 , wherein the subject is human.

Assignees

• 4D Pharma Res Ltd

Inventors

• MULDER Imke Elisabeth
• Yuille Samantha
• Ettorre Anna
• Ahmed Suaad
• Fotiadou Parthena
• Urcia Joseph Roby Iringan
• Savignac Helene

Classifications

• C12R2001/01

  Bacteria or Actinomycetales {; using bacteria or Actinomycetales} · CPC title

• C12N1/205

  Bacterial isolates · CPC title

• C12N1/20

  Bacteria; Culture media therefor · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61K39/0208

  Specific bacteria not otherwise provided for · CPC title